Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avicursen - Percheron Therapeutics

Next Previous
Drug Profile

Avicursen - Percheron Therapeutics

Alternative Names: ATL-1102; ATL/TV-1102; ISIS-107248; TV-1102

Latest Information Update: 28 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Antisense Therapeutics; Childrens Hospital Los Angeles; Percheron Therapeutics
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Antisense oligonucleotides
  • Mechanism of Action Integrin alpha4 inhibitors; Integrin alpha4beta1 antagonists; RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma; Multiple sclerosis

Highest Development Phases

  • Phase II Duchenne muscular dystrophy; Multiple sclerosis
  • No development reported Asthma; Cancer; Limb girdle muscular dystrophies
  • Discontinued Stem cell mobilisation; Vertigo

Most Recent Events

  • 28 Jul 2026 No recent reports of development identified for preclinical development in Limb-girdle-muscular-dystrophies in Australia
  • 24 Apr 2023 Phase-II clinical trials in Duchenne muscular dystrophy (In children, In adolescents) in Bulgaria (SC) as of April 2023 (EudraCT2022-003065-38)
  • 22 Jun 2022 Preclinical trials in Limb girdle muscular dystrophies in Australia (unspecified route)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top